{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:39:22Z","timestamp":1792291162290,"version":"4.4.0"},"reference-count":173,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"WROCLAW MEDICAL UNIVERSITY","doi-asserted-by":"publisher","award":["Mini.a431.024.008"],"award-info":[{"award-number":["Mini.a431.024.008"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ferroptosis, an iron-dependent form of regulated cell death marked by lipid peroxidation, has emerged as a promising therapeutic target in breast cancer, particularly in aggressive subtypes such as triple-negative breast cancer (TNBC). This systematic review explores the molecular mechanisms underlying ferroptosis sensitivity and resistance, focusing on the interplay between iron metabolism, antioxidant defenses, and tumor microenvironmental factors. Literature retrieved from PubMed and Scopus up to May was analyzed in accordance with PRISMA guidelines, including mechanistic studies, preclinical experiments, and ongoing clinical trials. Findings reveal that breast cancer cells evade ferroptosis through enhanced glutathione synthesis, upregulation of GPX4 and system Xc- and adaptive metabolic reprogramming; yet these same mechanisms create exploitable vulnerabilities, including dependence on cystine, polyunsaturated lipids, and dysregulated iron handling. Therapeutic strategies that target key ferroptosis regulators, such as GPX4, ACSL4, and SLC7A11, or that harness agents like statins, sulfasalazine, and nanoparticle-based iron complexes demonstrate strong potential to overcome chemoresistance and selectively eliminate therapy-resistant cancer cell populations. Taken together, the evidence highlights ferroptosis as a critical Achilles\u2019 heel of breast cancer biology and supports further clinical translation of ferroptosis-inducing therapies to improve outcomes in otherwise refractory breast cancer subtypes.<\/jats:p>","DOI":"10.3390\/ijms26209902","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T16:13:03Z","timestamp":1760717583000},"page":"9902","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeting Ferroptosis as the Achilles\u2019 Heel of Breast Cancer: Mechanisms and Therapeutic Opportunities from a Comprehensive Systematic Review"],"prefix":"10.3390","volume":"26","author":[{"given":"Anna","family":"Szulc","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Pathology, Division of General and Experimental Pathology, Wroclaw Medical University, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-6330","authenticated-orcid":false,"given":"Marta","family":"Wo\u017aniak","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Pathology, Division of General and Experimental Pathology, Wroclaw Medical University, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"ref_1","unstructured":"(2025, March 03). World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: A review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.2147\/CMAR.S176763","article-title":"Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: A population-based study","volume":"10","author":"Xiao","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: From biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.mayocp.2018.03.025","article-title":"Updates in the evaluation and management of breast cancer","volume":"93","author":"Loprinzi","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s12276-023-01069-y","article-title":"Regulated cell death pathways and their roles in homeostasis, infection, inflammation, and tumorigenesis","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, Q., Siddharth, S., and Sharma, D. (2021). Triple-negative breast cancer: A mountain yet to be scaled despite the triumphs. Cancers, 13.","DOI":"10.3390\/cancers13153697"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2016.6326","article-title":"Population-attributable risk proportion of clinical risk factors for breast cancer","volume":"3","author":"Engmann","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.20.24436","article-title":"Screening algorithms in dense breasts: AJR expert panel narrative review","volume":"216","author":"Berg","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJMoa062790","article-title":"Mammographic density and the risk and detection of breast cancer","volume":"356","author":"Boyd","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/j.jacr.2021.09.002","article-title":"ACR Appropriateness Criteria\u00ae Supplemental Breast Cancer Screening Based on Breast Density","volume":"18","author":"Weinstein","year":"2021","journal-title":"J. Am. Coll. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/jnci\/92.13.1081","article-title":"Breast density as a predictor of mammographic detection: Comparison of interval- and screen-detected cancers","volume":"92","author":"Mandelson","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/sj.bjc.6690158","article-title":"Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast","volume":"79","author":"Leek","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/1097-0142(19840201)53:3+<712::AID-CNCR2820531320>3.0.CO;2-I","article-title":"Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4) X. Discriminants for tenth year treatment failure","volume":"53","author":"Fisher","year":"1984","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00000478-200103000-00007","article-title":"Centrally necrotizing carcinomas of the breast: A distinct histologic subtype with aggressive clinical behavior","volume":"25","author":"Jimenez","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1158\/0008-5472.CAN-06-4353","article-title":"Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1081-1206(10)63176-6","article-title":"Apoptosis","volume":"78","author":"Fleisher","year":"1997","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev-cancerbio-030518-055844","article-title":"The hallmarks of ferroptosis","volume":"3","author":"Dixon","year":"2019","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: Past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"Biochem. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1800311","DOI":"10.1002\/pmic.201800311","article-title":"GPX4 at the crossroads of lipid homeostasis and ferroptosis","volume":"19","author":"Forcina","year":"2019","journal-title":"Proteomics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"R1292","DOI":"10.1016\/j.cub.2020.09.068","article-title":"Ferroptosis","volume":"30","author":"Tang","year":"2020","journal-title":"Curr. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","article-title":"Glutaminolysis and transferrin regulate ferroptosis","volume":"59","author":"Gao","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1111\/cas.14182","article-title":"Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma","volume":"110","author":"Okazaki","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molcel.2018.10.042","article-title":"Role of mitochondria in ferroptosis","volume":"73","author":"Gao","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41574-021-00499-w","article-title":"The role of regulated necrosis in endocrine diseases","volume":"17","author":"Tonnus","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: Mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108373","DOI":"10.1016\/j.pharmthera.2023.108373","article-title":"Molecular mechanisms of ferroptosis and their involvement in brain diseases","volume":"244","author":"Costa","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e20210518","DOI":"10.1084\/jem.20210518","article-title":"Ferroptosis in infection, inflammation, and immunity","volume":"218","author":"Chen","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.pharmthera.2012.11.003","article-title":"The Warburg effect: Insights from the past decade","volume":"137","author":"Upadhyay","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1113\/JP278810","article-title":"Revisiting the Warburg effect: Historical dogma versus current understanding","volume":"599","author":"Vaupel","year":"2021","journal-title":"J. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Szulc, A., and Wo\u017aniak, M. (2024). Targeting pivotal hallmarks of cancer for enhanced therapeutic strategies in triple-negative breast cancer treatment\u2014In vitro, in vivo and clinical trials literature review. Cancers, 16.","DOI":"10.3390\/cancers16081483"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Naik, A., and Decock, J. (2020). Lactate metabolism and immune modulation in breast cancer: A focused review on triple-negative breast tumors. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.598626"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tcb.2014.06.001","article-title":"Hypoxia, lipids, and cancer: Surviving the harsh tumor microenvironment","volume":"24","author":"Ackerman","year":"2014","journal-title":"Trends Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-cancerbio-041916-065808","article-title":"The two faces of reactive oxygen species in cancer","volume":"1","author":"Reczek","year":"2017","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-10-3323","article-title":"Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion","volume":"71","author":"Dirat","year":"2011","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.plipres.2017.11.002","article-title":"Adipocyte biology in breast cancer: From silent bystander to active facilitator","volume":"69","author":"Choi","year":"2018","journal-title":"Prog. Lipid Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e87489","DOI":"10.1172\/jci.insight.87489","article-title":"Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells","volume":"2","author":"Wang","year":"2017","journal-title":"JCI Insight"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-015-3550-9","article-title":"Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells","volume":"153","author":"Lee","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"47239","DOI":"10.18632\/oncotarget.17592","article-title":"Secretome analysis of breast cancer-associated adipose tissue to identify paracrine regulators of breast cancer growth","volume":"8","author":"Lapeire","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ayob, A.Z., and Ramasamy, T.S. (2018). Cancer stem cells as key drivers of tumour progression. J. Biomed. Sci., 25.","DOI":"10.1186\/s12929-018-0426-4"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zaoui, M., Morel, M., Ferrand, N., Fellahi, S., Bastard, J.P., Lamazi\u00e8re, A., Larsen, A.K., B\u00e9r\u00e9ziat, V., Atlan, M., and Sabbah, M. (2019). Breast-associated adipocytes secretome induce fatty acid uptake and invasiveness in breast cancer cells via CD36 independently of body mass index, menopausal status and mammary density. Cancers, 11.","DOI":"10.3390\/cancers11122012"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40170-016-0163-7","article-title":"Adipocyte lipolysis links obesity to breast cancer growth: Adipocyte-derived fatty acids drive breast cancer cell proliferation and migration","volume":"5","author":"Balaban","year":"2017","journal-title":"Cancer Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12964-018-0309-z","article-title":"Adipocyte-derived IL-6 and leptin promote breast cancer metastasis via upregulation of lysyl hydroxylase-2 expression","volume":"16","author":"He","year":"2018","journal-title":"Cell Commun. Signal."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2019.09.002","article-title":"Metabolic crosstalk in the breast cancer microenvironment","volume":"121","author":"Dias","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.7150\/thno.36037","article-title":"CD36 tango in cancer: Signaling pathways and functions","volume":"9","author":"Wang","year":"2019","journal-title":"Theranostics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5301\/ijbm.5000291","article-title":"Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients","volume":"33","author":"Ozretic","year":"2018","journal-title":"Int. J. Biol. Markers"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1073\/pnas.1104778108","article-title":"Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737","volume":"109","author":"Oakes","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000050608","article-title":"Bcl-2 expression and apoptosis in primary and metastatic breast carcinomas","volume":"22","author":"Villar","year":"2001","journal-title":"Tumour Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"104683","DOI":"10.1016\/j.phrs.2020.104683","article-title":"Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer","volume":"153","author":"Deepak","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-15-0490","article-title":"Autophagy, Metabolism, and Cancer","volume":"21","author":"White","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.cmet.2017.04.004","article-title":"Autophagy and Tumor Metabolism","volume":"25","author":"Kimmelman","year":"2017","journal-title":"Cell Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1080\/15548627.2016.1187366","article-title":"Autophagy Promotes Ferroptosis by Degradation of Ferritin","volume":"12","author":"Hou","year":"2016","journal-title":"Autophagy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4274\/balkanmedj.2017.0604","article-title":"Evaluation of the Cytotoxic and Autophagic Effects of Atorvastatin on MCF-7 Breast Cancer Cells","volume":"35","author":"Martinez","year":"2018","journal-title":"Balkan Med. J."},{"key":"ref_61","first-page":"e312","article-title":"ADIPOQ\/Adiponectin Induces Cytotoxic Autophagy in Breast Cancer","volume":"6","author":"Chung","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semcancer.2021.04.001","article-title":"Role of iron in cancer","volume":"76","author":"Salnikow","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/0929867033457638","article-title":"The role of iron chelation in cancer therapy","volume":"10","author":"Buss","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02829934","article-title":"A precious metal: Iron, an essential nutrient for all cells","volume":"1","author":"Cairo","year":"2006","journal-title":"Genes Nutr."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(80)90440-7","article-title":"Transferrin and transferrin receptors in carcinoma of the breast","volume":"2","author":"Faulk","year":"1980","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3495","article-title":"Iron and cancer: More ore to be mined","volume":"13","author":"Torti","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1158\/0008-5472.CAN-09-1934","article-title":"Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis","volume":"69","author":"Leng","year":"2009","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1097-2765(02)00708-6","article-title":"The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition","volume":"10","author":"Goetz","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Asimakopoulou, A., Weiskirchen, S., and Weiskirchen, R. (2016). Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy. Front. Physiol., 7.","DOI":"10.3389\/fphys.2016.00430"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","article-title":"Two to Tango: Regulation of Mammalian Iron Metabolism","volume":"142","author":"Hentze","year":"2010","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1038\/emm.2017.273","article-title":"Differential Regulation of Hepcidin in Cancer and Non-Cancer Tissues and Its Clinical Implications","volume":"50","author":"Vela","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1038\/s41388-018-0243-y","article-title":"Contribution of Three-Dimensional Architecture and Tumor-Associated Fibroblasts to Hepcidin Regulation in Breast Cancer","volume":"37","author":"Kita","year":"2018","journal-title":"Oncogene"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"43ra56","DOI":"10.1126\/scitranslmed.3001127","article-title":"Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis","volume":"2","author":"Pinnix","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0006-291X(83)91040-9","article-title":"Continual Presence of Oxygen and Iron Required for Mammalian Ribonucleotide Reduction: Possible Regulation Mechanism","volume":"110","author":"Thelander","year":"1983","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1016\/S0021-9258(18)89423-6","article-title":"Subunit M2 of Mammalian Ribonucleotide Reductase. Characterization of a Homogeneous Protein Isolated from M2-Overproducing Mouse Cells","volume":"260","author":"Thelander","year":"1985","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","article-title":"Targeting Ferroptosis to Iron Out Cancer","volume":"35","author":"Hassannia","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Dufrusine, B., Di Francesco, A., Oddi, S., Scipione, L., Angelucci, C.B., D\u2019Addario, C., Di Francesco, A., Catacuzzeno, L., Franciolini, F., and Dainese, E. (2019). Iron-Dependent Trafficking of 5-Lipoxygenase and Impact on Human Macrophage Activation. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01347"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.blre.2008.08.001","article-title":"Ferritin for the Clinician","volume":"23","author":"Knovich","year":"2009","journal-title":"Blood Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-010-0849-4","article-title":"Role of Ferritin Alterations in Human Breast Cancer Cells","volume":"126","author":"Shpyleva","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.bbagen.2008.09.004","article-title":"Ferritins: A Family of Molecules for Iron Storage, Antioxidation and More","volume":"1790","author":"Arosio","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1470-2045(08)70200-6","article-title":"Does Iron Have a Role in Breast Cancer?","volume":"9","author":"Huang","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_83","first-page":"1513","article-title":"Antisense Ferritin Oligonucleotides Inhibit Growth and Induce Apoptosis in Human Breast Carcinoma Cells","volume":"22","author":"Yang","year":"2002","journal-title":"Anticancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1039\/C6MT00100A","article-title":"Iron Speciation, Ferritin Concentrations and Fe:Ferritin Ratios in Different Malignant Breast Cancer Cell Lines: On the Search for Cancer Biomarkers","volume":"8","year":"2016","journal-title":"Metallomics"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to Clinic: Glutamine Metabolism to Cancer Therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/onc.2015.381","article-title":"ASCT2\/SLC1A5 Controls Glutamine Uptake and Tumour Growth in Triple-Negative Basal-Like Breast Cancer","volume":"35","author":"Wang","year":"2016","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13058-018-0946-6","article-title":"The Amino Acid Transporter SLC7A5 Confers a Poor Prognosis in the Highly Proliferative Breast Cancer Subtypes and Is a Key Therapeutic Target in Luminal B Tumours","volume":"20","author":"Craze","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2016.34.15_suppl.1011","article-title":"Phase 1 Study of CB-839, a Small Molecule Inhibitor of Glutaminase (GLS) in Combination with Paclitaxel (Pac) in Patients (Pts) with Triple-Negative Breast Cancer (TNBC)","volume":"34","author":"DeMichele","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Cao, M.D., Lamichhane, S., Lundgren, S., Bofin, A., Fj\u00f8sne, H., Giske\u00f8deg\u00e5rd, G.F., and Bathen, T.F. (2014). Metabolic Characterization of Triple-Negative Breast Cancer. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-941"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccr.2013.08.020","article-title":"Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target","volume":"24","author":"Timmerman","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"107864","DOI":"10.1016\/j.pharmthera.2021.107864","article-title":"In Cancer, All Roads Lead to NADPH","volume":"226","author":"Rather","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Song, X., Wang, X., Liu, Z., and Yu, Z. (2020). Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple-Negative Breast Cancer Cells to Gefitinib. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.597434"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","article-title":"HLF Regulates Ferroptosis, Development and Chemoresistance of Triple-Negative Breast Cancer by Activating Tumor Cell-Macrophage Crosstalk","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Gan, B. (2021). Mitochondrial Regulation of Ferroptosis. J. Cell Biol., 220.","DOI":"10.1083\/jcb.202105043"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 Dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_96","first-page":"5405","article-title":"Metabolic Networks in Ferroptosis","volume":"15","author":"Hao","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kalinina, E. (2024). Glutathione-Dependent Pathways in Cancer Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158423"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12967-020-02420-x","article-title":"Involvement of Glutathione Peroxidases in the Occurrence and Development of Breast Cancers","volume":"18","author":"Zhang","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1038\/onc.2016.394","article-title":"Cystine Addiction of Triple-Negative Breast Cancer Associated with EMT Augmented Death Signaling","volume":"36","author":"Tang","year":"2017","journal-title":"Oncogene"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, H., Chen, N., Ding, C., Zhang, H., Liu, D., and Liu, S. (2024). Ferroptosis and EMT Resistance in Cancer: A Comprehensive Review of the Interplay. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1344290"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature24297","article-title":"Drug-Tolerant Persister Cancer Cells Are Vulnerable to GPX4 Inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbagen.2011.10.013","article-title":"Regulation of Iron Transport and the Role of Transferrin","volume":"1820","author":"Gkouvatsos","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cmet.2015.09.006","article-title":"Ironing Out Ferroportin","volume":"22","author":"Drakesmith","year":"2015","journal-title":"Cell Metab."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.1039\/C5CS00541H","article-title":"In Vivo Delivery, Pharmacokinetics, Biodistribution and Toxicity of Iron Oxide Nanoparticles","volume":"44","author":"Arami","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0300-9084(93)90126-D","article-title":"Iron: Metabolism, Toxicity and Therapy","volume":"75","author":"Fontecave","year":"1993","journal-title":"Biochimie"},{"key":"ref_106","first-page":"29094","article-title":"Carbon Nanoparticles-Fe(II) Complex for Efficient Tumor Inhibition with Low Toxicity by Amplifying Oxidative Stress","volume":"12","author":"Xie","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_107","unstructured":"(2025, April 25). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06048367."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41416-018-0287-3","article-title":"Dasatinib Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy by Targeting Breast Cancer Stem Cells","volume":"119","author":"Tian","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10549-018-05100-z","article-title":"Efficacy and Safety of Dasatinib with Trastuzumab and Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer: Results from the Phase II GEICAM\/2010-04 Study","volume":"174","author":"Ocana","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Wang, L., Xiong, B., Lu, W., Cheng, Y., Zhu, J., Ai, G., Zhang, X., Liu, X., and Cheng, Z. (2024). Senolytic Drugs Dasatinib and Quercetin Combined with Carboplatin or Olaparib Reduced the Peritoneal and Adipose Tissue Metastasis of Ovarian Cancer. Biomed. Pharmacother., 174.","DOI":"10.1016\/j.biopha.2024.116474"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5299218","DOI":"10.1155\/2022\/5299218","article-title":"Quercetin Promotes TFEB Nuclear Translocation and Activates Lysosomal Degradation of Ferritin to Induce Ferroptosis in Breast Cancer Cells","volume":"2022","author":"An","year":"2022","journal-title":"Comput. Intell. Neurosci."},{"key":"ref_113","unstructured":"(2025, April 26). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06355037."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.drudis.2020.04.003","article-title":"The Combination of Disulfiram and Copper for Cancer Treatment","volume":"25","author":"Li","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Ren, X., Li, Y., Zhou, Y., Hu, W., Yang, C., Jing, Q., Zhou, C., Wang, X., Hu, J., and Wang, L. (2021). Overcoming the Compensatory Elevation of NRF2 Renders Hepatocellular Carcinoma Cells More Vulnerable to Disulfiram\/Copper-Induced Ferroptosis. Redox Biol., 46.","DOI":"10.1016\/j.redox.2021.102122"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jconrel.2020.01.001","article-title":"Old Wine in New Bottles: Advanced Drug Delivery Systems for Disulfiram-Based Cancer Therapy","volume":"319","author":"McMahon","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Chu, M., An, X., Fu, C., Yu, H., Zhang, D., Li, Q., Man, X., Dai, X., and Li, Z. (2023). Disulfiram\/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231. Front. Biosci., 28.","DOI":"10.31083\/j.fbl2808186"},{"key":"ref_118","unstructured":"(2025, April 27). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03323346."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000199652","article-title":"Prospective, Randomized, Double-Blind Comparison of Benzalazine and Sulfasalazine in the Treatment of Active Ulcerative Colitis","volume":"40","author":"Fleig","year":"1988","journal-title":"Digestion"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/ard.2007.087106","article-title":"Efficacy, Safety and Patient-Reported Outcomes of Combination Etanercept and Sulfasalazine versus Etanercept Alone in Patients with Rheumatoid Arthritis: A Double-Blind Randomised 2-Year Study","volume":"68","author":"Combe","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.leu.2402238","article-title":"Sulfasalazine, a Potent Suppressor of Lymphoma Growth by Inhibition of the x(c)- Cystine Transporter: A New Action for an Old Drug","volume":"15","author":"Gout","year":"2001","journal-title":"Leukemia"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10585-009-9277-4","article-title":"Cancer Cell Lines Release Glutamate into the Extracellular Environment","volume":"26","author":"Seidlitz","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbrc.2009.10.168","article-title":"Cancer Cells Release Glutamate via the Cystine\/Glutamate Antiporter","volume":"391","author":"Sharma","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Gayt\u00e1n, A.C., Hern\u00e1ndez-Abrego, A., D\u00edaz-Mu\u00f1oz, M., and M\u00e9ndez, I. (2022). Glutamatergic System Components as Potential Biomarkers and Therapeutic Targets in Cancer in Non-Neural Organs. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1029210"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pain.2013.08.030","article-title":"Inhibition of Breast Cancer-Cell Glutamate Release with Sulfasalazine Limits Cancer-Induced Bone Pain","volume":"155","author":"Ungard","year":"2014","journal-title":"Pain"},{"key":"ref_126","unstructured":"(2025, April 27). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03847311."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","article-title":"Statin drugs to reduce breast cancer recurrence and mortality","volume":"20","author":"Beckwitt","year":"2018","journal-title":"Breast Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jnci\/djr291","article-title":"Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study","volume":"103","author":"Ahern","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_129","first-page":"1539","article-title":"Joint societies CVD prevention guidelines launched in May 2012","volume":"33","author":"Taylor","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"28110","DOI":"10.1074\/jbc.M001280200","article-title":"Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine","volume":"275","author":"Warner","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-17-1231","article-title":"Statin-induced cancer cell death can be mechanistically uncoupled from prenylation of RAS family proteins","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cell.2007.01.049","article-title":"Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation","volume":"129","author":"Lau","year":"2007","journal-title":"Cell"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1158\/0008-5472.CAN-20-2642","article-title":"Mevalonate pathway inhibition slows breast cancer metastasis via reduced N-glycosylation abundance and branching","volume":"81","author":"Yu","year":"2021","journal-title":"Cancer Res."},{"key":"ref_134","unstructured":"(2025, April 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05550415."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2014Mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem. J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13046-021-02012-7","article-title":"Metformin induces ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer","volume":"40","author":"Yang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1200\/JCO.2016.69.7722","article-title":"Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: Analysis from the ALTTO phase III randomized trial","volume":"35","author":"Sonnenblick","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PRS.0000000000005647","article-title":"The role of deferoxamine in irradiated breast reconstruction: A study of oncologic safety","volume":"143","author":"Lynn","year":"2019","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V89.8.3025","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone","volume":"89","author":"Richardson","year":"1997","journal-title":"Blood"},{"key":"ref_141","first-page":"3968","article-title":"Neuroblastoma sensitivity to growth inhibition by deferrioxamine: Evidence for a block in G1 phase of the cell cycle","volume":"53","author":"Brodie","year":"1993","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.4103\/1673-5374.274344","article-title":"Neuroprotective effect of deferoxamine on erastin-induced ferroptosis in primary cortical neurons","volume":"15","author":"Zhang","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11064-021-03262-9","article-title":"Benefits of iron chelators in the treatment of Parkinson\u2019s disease","volume":"46","author":"Zeng","year":"2021","journal-title":"Neurochem. Res."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Liu, Y., Hu, Y., Jiang, Y., Bu, J., and Gu, X. (2022). Targeting ferroptosis, the Achilles\u2019 heel of breast cancer: A review. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1036140"},{"key":"ref_145","unstructured":"(2025, April 29). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05300958."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Choi, H., Gupta, M., Hensley, C., Lee, H., Lu, Y.T., Pantel, A., Mankoff, D., and Zhou, R. (2023). Disruption of redox balance in glutaminolytic triple-negative breast cancer by inhibition of glutamate export and glutaminase. bioRxiv.","DOI":"10.1101\/2023.11.19.567663"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","article-title":"Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy","volume":"21","author":"Shi","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ctrv.2013.09.002","article-title":"A systematic review of dual targeting in HER2-positive breast cancer","volume":"40","author":"Tuxen","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/bjc.2013.178","article-title":"Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer","volume":"108","author":"Chow","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_151","unstructured":"(2025, May 05). U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neratinib-metastatic-her2-positive-breast-cancer."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u22652 HER2-directed regimens: Phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.18632\/oncotarget.1148","article-title":"Neratinib overcomes trastuzumab resistance in HER2-amplified breast cancer","volume":"4","author":"Canonici","year":"2013","journal-title":"Oncotarget"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13058-019-1177-1","article-title":"Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ breast cancer metastasis","volume":"21","author":"Nagpal","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.2147\/DDDT.S207720","article-title":"Escin: A review of its anti-edematous, anti-inflammatory, and venotonic properties","volume":"13","author":"Gallelli","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4103\/jmss.JMSS_44_18","article-title":"Activation of p53 gene expression and synergistic antiproliferative effects of 5-fluorouracil and beta-escin on MCF7 cells","volume":"9","author":"Mazrouei","year":"2019","journal-title":"J. Med. Signals Sens."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1007\/s11033-022-07536-5","article-title":"Beta-escin reduces cancer progression in aggressive MDA-MB-231 cells by inhibiting glutamine metabolism through downregulation of c-myc oncogene","volume":"49","author":"Akar","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s10495-023-01849-x","article-title":"Role of escin in breast cancer therapy: Potential mechanism for inducing ferroptosis and synergistic antitumor activity with cisplatin","volume":"28","author":"Li","year":"2023","journal-title":"Apoptosis"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bj.2020.08.001","article-title":"G6PD: A hub for metabolic reprogramming and redox signaling in cancer","volume":"44","author":"Yang","year":"2021","journal-title":"Biomed. J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e2402827","DOI":"10.1002\/adhm.202402827","article-title":"K2FeO4-enhanced photodynamic therapy of breast cancer via in situ synthesis of Fe2O3 and O2","volume":"14","author":"Sun","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"ref_161","first-page":"85","article-title":"The effects of the novel, reversible epidermal growth factor receptor\/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo","volume":"1","author":"Rusnak","year":"2001","journal-title":"Mol. Cancer Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e2307","DOI":"10.1038\/cddis.2016.208","article-title":"Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells","volume":"7","author":"Ma","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Ma, S., Dielschneider, R.F., Henson, E.S., Xiao, W., Choquette, T.R., Blankstein, A.R., Chen, Y., and Gibson, S.B. (2017). Ferroptosis and autophagy-induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182921"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Sun, C., Liu, P., Pei, L., Zhao, M., and Huang, Y. (2022). Propofol inhibits proliferation and augments the anti-tumor effect of doxorubicin and paclitaxel partly through promoting ferroptosis in triple-negative breast cancer cells. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.837974"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ijc.28159","article-title":"Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib","volume":"133","author":"Louandre","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1126\/science.aaw9872","article-title":"Cysteine depletion induces pancreatic tumor ferroptosis in mice","volume":"368","author":"Badgley","year":"2020","journal-title":"Science"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.trecan.2021.04.005","article-title":"Targeting ferroptosis in pancreatic cancer: A double-edged sword","volume":"7","author":"Chen","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CAD.0000000000001561","article-title":"Clusterin is upregulated by erastin, a ferroptosis inducer, and exerts cytoprotective effects in pancreatic adenocarcinoma cells","volume":"35","author":"Li","year":"2024","journal-title":"Anticancer Drugs"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ccell.2023.05.001","article-title":"CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis","volume":"41","author":"Minami","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2915019","DOI":"10.1155\/2021\/2915019","article-title":"RSL3 drives ferroptosis through NF-\u03baB pathway activation and GPX4 depletion in glioblastoma","volume":"2021","author":"Li","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"4930643","DOI":"10.1155\/2022\/4930643","article-title":"Ferroptosis induction improves the sensitivity of docetaxel in prostate cancer","volume":"2022","author":"Chen","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e2307263","DOI":"10.1002\/advs.202307263","article-title":"Programming a ferroptosis-to-apoptosis transition landscape revealed ferroptosis biomarkers and repressors for cancer therapy","volume":"11","author":"Vinik","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Lin, Y.S., Shen, Y.C., Wu, C.Y., Tsai, Y.Y., Yang, Y.H., Lin, Y.Y., Kuan, F.C., Lu, C.N., Chang, G.H., and Tsai, M.S. (2019). Danshen improves survival of patients with breast cancer and dihydroisotanshinone I induces ferroptosis and apoptosis of breast cancer cells. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01226"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/9902\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:57:13Z","timestamp":1760968633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/9902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":173,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26209902"],"URL":"https:\/\/doi.org\/10.3390\/ijms26209902","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]}}}